Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Eli Lilly is buying Insilico Medicine https://www.ftc.gov/legal-library/browse/early-termination-notices/20261000

Xenotransplantation case: transplantation of organ (liver) from one bio kind (pig) to human: https://doi.org/10.1016/j.jhep.2025.08.044

https://www.nature.com/articles/s41586-026-10235-x Now, immune cells can be "reprogrammed" directly within the body during cancer treatment, without being removed. Currently, CAR-T therapy works like this: T cells are removed from the patient, sent to a lab, genetically modified, and then returned. This takes weeks and costs approximately $400,000-$500,000. Additionally, the patient often needs to undergo intensive chemotherapy before the procedure. The new approach eliminates all of this. Instead of complex logistics, it uses a system of two nanoparticles administered in a single injection. The first particle delivers the famous CRISPR-Cas9, the "molecular scissors" that cut DNA at a precise location, to the T cells. The second particle carries the CAR gene itself—the instructions that transform a normal T cell into a cancer-killing cell. The key technical breakthrough is that DNA insertion occurs precisely at a specific point in the genome, rather than randomly, as in classical methods. This reduces the risk of side effects, including secondary tumors. The system is also configured to work only in T cells. This is achieved through a kind of "molecular switch" that is activated only in these cells. This is critical because the body has no way to filter out incorrectly modified cells, as is done in the laboratory. The results in mice with a "humanized" immune system appear very strong. After a single injection, cancer disappeared in almost all animals in just two weeks. Modified T cells accounted for up to 40 percent of immune cells in some organs and effectively destroyed tumors in both the bone marrow and spleen. The method worked not only against leukemia, but also against multiple myeloma and sarcoma—this is especially important because solid tumors typically respond poorly to CAR-T therapy. Interestingly, T cells created directly in the body were even more effective than those produced in the laboratory. It is believed that when grown outside the body, the cells lose some of their properties—their so-called "stemness" and their ability to proliferate. This does not occur inside the body.

While OpenAI & others thinking to make an AI Scientist, we are building it: https://www.technologyreview.com/2026/03/20/1134438/openai-is-throwing-everything-into-building-a-fully-automated-researcher/

«This one is difficult. Prescription drug royalties in exchange for access to AI models seems like a solution looking for a problem to solve. If it attempts to solve anything, it is just OpenAI’s own revenue struggles. AI-driven drug discovery, you see, is a very intricate combo of your own proprietary platform/moat, pre-clinical/regulatory/clinical ability and, after all, efficient BD. It is incorrect to assume that the drug discovery itself is the bottleneck for biotechs, it’s the proving process. No AI model will help them avoid the years of lab validation, preclinical work, the regulatory process and BD. All topped up with all the costs involved. Reed Albergotti at SEMAFOR nails this: giving away software for free in exchange for downstream royalties only works if the software actually shortens timelines or improves success rates. Right now, it doesn't. Especially if it is not unique to a specific company. Look at Insilico Medicine for reference - it takes to be an end-to-end AI-infused pharma to be successful, not just "have the access to an AI model". As a biotech VC, LongeVC sees this pitch all the time. Founders love to claim their AI will "revolutionize” their corner of longevity/healthtech. In many cases, it will not. But, when we have backed startups using AI, what really moves the needle (and therefore gets funded) is a) AI that demonstrably reduces experimental cycles and increases hit rates; b) pre-clinical/regulatory and clinical understanding; c) BD logic able to put together a comprehensive pipeline of candidates to strike early deals and keep the best assets to yourself» Agree!

Australian Paul Coningham created a personalized cancer vaccine for his dog Rosie using ChatGPT. The viral story of how "one man with a chatbot beat pharma" sounds impressive, but the real story is far more complex and interesting. In 2024, Coningham learned that Rosie had mast cell cancer, a common and nearly incurable form of cancer in dogs. Surgery and chemotherapy slowed the disease but did not stop it. In December 2025, Rosie received her first injection of the personalized mRNA vaccine. By January, the tumor had shrunk by half, her fur was shiny again, and she was jumping fences. The media describes Coningham as a "tech entrepreneur without a biology background," but in reality, he is a veteran of machine learning and data science, co-founder of Core Intelligence Technologies in Sydney, with decades of experience working with data processing pipelines. For him, ChatGPT was a tool for an experienced specialist, not a magic "create a vaccine" button. AI helped suggest a direction—immunotherapy—and pointed him to the UNSW Ramaciotti Genomics Centre. Professor Martin Smith recalls that the centre doesn't typically support direct-to-consumer DNA sequencing, but Coningham assured him, "Don't worry, I'm a data analyst; I can figure it out with ChatGPT." He then used AlphaFold to predict 3D structures of mutated proteins and his own ML algorithms to select neoantigens. He passed the resulting data to Professor Páll Torgdarson of the UNSW RNA Institute, who synthesized the nanoparticle. The vaccine was administered by Professor Rachel Allavena of the University of Queensland, the only veterinarian with permission to conduct such experiments. It's important to emphasize that the AI ​​didn't create the vaccine on its own. It accelerated the analysis and research process, which would have taken months without it. Experimental procedures in animals are regulated differently than in humans, so the time from vaccine design to the first injection was less than two months. For human drugs, such a process would take years and be significantly more expensive. Personalized mRNA cancer vaccines are not science fiction. Moderna and Merck have already demonstrated a 44% reduction in the risk of melanoma recurrence compared to monotherapy, and Phase III trials are currently underway for melanoma and non-small cell lung cancer. Professor Torgdarson notes that Coningham's achievement is astounding, as AI has lowered the entry barrier to tasks that previously required an entire team to the level of a single person with the necessary experience and tools.

Forget drugs. This $233 million bet treats Alzheimer's with flickering light and sound. And is changing therapy! Cognito Therapeutics just closed an oversubscribed $105 million Series C. Not for a new molecule. Not for another antibody. For a headset. A headset that delivers 40Hz light and sound stimulation for one hour a day. From home. Non-invasive. No injections. No infusion centers. This is not science fiction. This is based on a decade of MIT neuroscience research. Here's what you need to know. → Alzheimer's patients have disrupted neuronal activity in the brain. Gamma oscillations at 40Hz are weakened. → MIT's Dr. Li-Huei Tsai discovered that non-invasive 40Hz audiovisual stimulation can re-engage these disrupted brain rhythms. → In animal studies, this reduced amyloid and tau proteins, preserved neurons, and sustained memory. → Cognito built Spectris, a headset that brings this therapy into patients' homes. The clinical results from the OVERTURE feasibility study are striking: → 77% reduction in decline of daily function → 76% reduction in cognitive decline → 69% reduction in brain volume loss → 85% patient adherence to daily treatment All compared to the control group. Over 6 months. And it doesn't stop there. → Long-term data from a 30-month study showed continued slowing of brain atrophy. → The FDA granted Spectris Breakthrough Device Designation. Cognito's pivotal HOPE Study is now fully enrolled with up to 670 patients across the U.S. Data readout is expected this year. FDA submission is planned for 2026. Commercialization target: 2027. Total funding to date: $233 million. Why this matters beyond Alzheimer's: → Non-pharmacological. No drug side effects. → Home-based. Scalable. Accessible. → Cognito is already expanding Spectris into other neurodegenerative conditions. I've been covering health innovation for years. And this is one of the most exciting signals I've seen. Not because it replaces everything else. But because it opens an entirely new category of treatment. One that doesn't depend on Big Pharma pipelines. One that can reach patients at home. One that attacks Alzheimer's from a completely different angle: restoring brain rhythm, not just removing plaques. Alzheimer's affects 55 million people worldwide. Current treatments are expensive, limited, and often come with serious side effects. If Spectris delivers in the pivotal trial, we're looking at a paradigm shift. From clinic visits to your living room. The future of Alzheimer's care might not come in a pill. It might come in a headset. What do you think: can non-drug therapies like this change the game for neurodegenerative diseases? Sources: Business Wire, STAT News, MIT News, Cognito Therapeutics, MobiHealthNews